About Mirna Therapeutics (NASDAQ:SYBX)
Synlogic, Inc., formerly Mirna Therapeutics, Inc., is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU). It is also focused on Synthetic Biotic medicines to address other conditions, including inflammatory bowel disease , cancer and metabolic conditions, such as diabetes and obesity. The Company's synthetic biotic medicines leverages the tools and principles of synthetic biology to genetically reengineer probiotic microbes to perform or deliver critical functions missing or damaged due to disease. The Company's pipeline includes synthetic biotic medicines for the treatment of inborn errors of metabolism (IEM). It is developing SYNB1020 for the treatment of UCD and HE. It is developing SYNB1618 for the treatment of PKU.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biopharmaceuticals
- Sub-Industry: N/A
- Symbol: NASDAQ:SYBX
- CUSIP: N/A
- Web: www.mirnarx.com
Capitalization:- Market Cap: $275.5 million
- Outstanding Shares: 16,282,000
Average Prices:- 50 Day Moving Avg: $17.00
- 200 Day Moving Avg: $13.39
- 52 Week Range: $7.84 - $23.00
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -10.98
- P/E Growth: 0.00
Profitability:- Return on Equity: -44.70%
- Return on Assets: -42.29%
Debt:- Current Ratio: 33.87%
- Quick Ratio: 33.87%
Misc:- Average Volume: 16,852 shs.
- Beta: 4
Frequently Asked Questions for Mirna Therapeutics (NASDAQ:SYBX)
What is Mirna Therapeutics' stock symbol?
Mirna Therapeutics trades on the NASDAQ under the ticker symbol "SYBX."
When did Mirna Therapeutics' stock split? How did Mirna Therapeutics' stock split work?
Mirna Therapeutics shares reverse split on Monday, August 28th 2017. The 1-7 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 25th 2017. An investor that had 100 shares of Mirna Therapeutics stock prior to the reverse split would have 14 shares after the split.
Where is Mirna Therapeutics' stock going? Where will Mirna Therapeutics' stock price be in 2017?
3 brokers have issued twelve-month price objectives for Mirna Therapeutics' stock. Their forecasts range from $14.00 to $25.00. On average, they expect Mirna Therapeutics' stock price to reach $19.50 in the next twelve months. View Analyst Ratings for Mirna Therapeutics.
Who are some of Mirna Therapeutics' key competitors?
Some companies that are related to Mirna Therapeutics include Syros Pharmaceuticals (SYRS), Sinovac Biotech (SVA), ChemoCentryx (CCXI), Syndax Pharmaceuticals (SNDX), Strongbridge Biopharma PLC (SBBP), Fortress Biotech (FBIO), Mereo BioPharma Group PLC (MPH), Kadmon Holdings (KDMN), Kamada (KMDA), Peregrine Pharmaceuticals (PPHM), Vericel Corporation (VCEL), MediWound (MDWD), Alimera Sciences (ALIM), KalVista Pharmaceuticals (KALV), VIVUS (VVUS), Opiant Pharmaceuticals (OPNT), Cardiome Pharma Corporation (CRME) and Chiasma (CHMA).
Who are Mirna Therapeutics' key executives?
Mirna Therapeutics' management team includes the folowing people:
- Michael F. Powell Ph.D., Chairman of the Board
- Jose Carlos Gutierrez-Ramos Ph.D., President, Chief Executive Officer, Director
- Todd Shegog, Chief Financial Officer, Secretary
- Paul Miller, Chief Scientific Officer
- Jay Stoudemire Ph.D., Vice President - Preclinical Development, Regulatory and Quality Assurance
- Aoife M. Brennan, Chief Medical Officer
- Casi DeYoung, Chief Business Officer
- Edward T. Mathers, Independent Director
How do I buy Mirna Therapeutics stock?
Shares of Mirna Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Mirna Therapeutics' stock price today?
One share of Mirna Therapeutics stock can currently be purchased for approximately $16.47.
MarketBeat Community Rating for Mirna Therapeutics (NASDAQ SYBX)MarketBeat's community ratings are surveys of what our community members think about Mirna Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Mirna Therapeutics (NASDAQ:SYBX) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 2 Hold Ratings, 1 Buy Rating |
| Consensus Rating: | Hold (Score: 2.33) |
| Consensus Price Target: | $19.50 (18.40% upside) |
Consensus Price Target History for Mirna Therapeutics (NASDAQ:SYBX)
Analysts' Ratings History for Mirna Therapeutics (NASDAQ:SYBX)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/19/2017 | Leerink Swann | Initiated Coverage | Outperform -> Outperform | $25.00 | Low |  |
| 4/13/2017 | Cantor Fitzgerald | Reiterated Rating | Hold | $14.00 | Low | |
| 11/15/2016 | HC Wainwright | Reiterated Rating | Hold | | N/A | |
| 9/22/2016 | Citigroup Inc. | Lower Price Target | Neutral | $31.50 -> $14.00 | N/A | |
| 9/21/2016 | Oppenheimer Holdings, Inc. | Downgrade | Outperform -> Market Perform | | N/A | |
(Data available from 10/20/2015 forward)
Earnings History for Mirna Therapeutics (NASDAQ:SYBX)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Mirna Therapeutics (NASDAQ:SYBX)| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q3 2017 | 1 | ($0.50) | ($0.50) | ($0.50) |
| Q4 2017 | 1 | ($0.50) | ($0.50) | ($0.50) |
(Data provided by Zacks Investment Research)
Dividend History for Mirna Therapeutics (NASDAQ:SYBX)
No dividend announcements for this company have been tracked by MarketBeat.com
Headline Trends for Mirna Therapeutics (NASDAQ:SYBX)
Latest Headlines for Mirna Therapeutics (NASDAQ:SYBX)
| Source: |
|
Mirna Therapeutics (SYBX) Chart for Friday, October, 20, 2017
